Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | KDR | P35968 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 2/20 | 0.42 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 4/20 | 0.41 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.40 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.40 |
| ▸ | CASR | P41180 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5565031 | 0.84 | CNR1 (0.55) | MEN1KMT2AHTTPOLBMAPT | |
| SCHEMBL6719504 | 0.80 | MAPT (0.49) | MEN1KMT2AHTTPOLBMAPT | |
| SCHEMBL5565500 | 0.79 | MAPT (0.48) | MEN1KMT2AHTTPOLBMAPT | |
| SCHEMBL5779764 | 0.77 | KMT2A (0.52) | MEN1KMT2AHTTPOLBMAPT | |
| SCHEMBL15601909 | 0.76 | MAPT (0.53) | MEN1KMT2AHTTPOLBMAPT | |
| SCHEMBL2597849 | 0.75 | HTT (0.64) | MEN1KMT2AHTTPOLBMAPT | |
| SCHEMBL5565486 | 0.74 | MAPT (0.51) | MEN1KMT2AHTTPOLBMAPT | |
| SCHEMBL6719494 | 0.73 | MAPT (0.50) | MEN1KMT2AHTTPOLBMAPT | |
| SCHEMBL6152067 | 0.73 | CNR1 (0.52) | MEN1KMT2AHTTMAPTCNR1 | |
| SCHEMBL10781905 | 0.72 | MAPT (0.67) | MEN1KMT2AHTTMAPTCNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7229479-B2 | Method of coloring porous material | CIBA SPECIALTY CHEMICALS CORPORATION (US) | 2007-06-12 | — | — | US | disclosed |
| US-20060162095-A1 | Method of colouring porous material | CIBA SPECIALTY CHEMICALS CORP. | 2006-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060162095-A1 | Method of colouring porous material | ACR, HLA-C, TYR | MEN1 615/4885KMT2A 3603/4885HTT 156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.